Structure-based 3D-QSAR—merging the accuracy of structure-based alignments with the computational efficiency of ligand-based methods
暂无分享,去创建一个
[1] C G Wermuth,et al. Aminopyridazines--an alternative route to potent muscarinic agonists with no cholinergic syndrome. , 1993, Farmaco.
[2] H. Kubinyi,et al. 3D QSAR in drug design. , 2002 .
[3] J. Sussman,et al. Quaternary ligand binding to aromatic residues in the active-site gorge of acetylcholinesterase. , 1994, Proceedings of the National Academy of Sciences of the United States of America.
[4] Yuan-Ping Pang,et al. Structure of acetylcholinesterase complexed with the nootropic alkaloid, (–)-huperzine A , 1997, Nature Structural Biology.
[5] C. Wermuth,et al. Aminopyridazines as acetylcholinesterase inhibitors. , 1999, Journal of medicinal chemistry.
[6] N Heinrich,et al. Three-dimensional models of estrogen receptor ligand binding domain complexes, based on related crystal structures and mutational and structure-activity relationship data. , 1998, Journal of medicinal chemistry.
[7] E. Giacobini,et al. From molecular structure to Alzheimer therapy. , 1997, Japanese journal of pharmacology.
[8] G. Cruciani,et al. Comparative molecular field analysis using GRID force-field and GOLPE variable selection methods in a study of inhibitors of glycogen phosphorylase b. , 1994, Journal of medicinal chemistry.
[9] Erwin von Angerer,et al. The Estrogen Receptor as a Target for Rational Drug Design , 1995 .
[10] Yun Tang,et al. Molecular Modeling and 3D-QSAR Studies on the Interaction Mechanism of Tripeptidyl Thrombin Inhibitors with Human α-Thrombin† , 1997 .
[11] C. Lemmen,et al. FLEXS: a method for fast flexible ligand superposition. , 1998, Journal of medicinal chemistry.
[12] R. Cramer,et al. Comparative molecular field analysis (CoMFA). 1. Effect of shape on binding of steroids to carrier proteins. , 1988, Journal of the American Chemical Society.
[13] R A Goldstein,et al. Three-dimensional model for the hormone binding domains of steroid receptors. , 1993, Proceedings of the National Academy of Sciences of the United States of America.
[14] John A. Katzenellenbogen,et al. The estradiol pharmacophore: Ligand structure-estrogen receptor binding affinity relationships and a model for the receptor binding site , 1997, Steroids.
[15] A. Olson,et al. Modelling of Factor Xa‐inhibitor complexes: a computational flexible docking approach , 1999, Proteins.
[16] A. Goldman,et al. Atomic structure of acetylcholinesterase from Torpedo californica: a prototypic acetylcholine-binding protein , 1991, Science.
[17] I. Kuntz,et al. Automated docking with grid‐based energy evaluation , 1992 .
[18] Mark von Itzstein,et al. A structural and energetics analysis of the binding of a series of N-acetylneuraminic-acid-based inhibitors to influenza virus sialidase , 1996, J. Comput. Aided Mol. Des..
[19] A Wlodawer,et al. An approach to rapid estimation of relative binding affinities of enzyme inhibitors: application to peptidomimetic inhibitors of the human immunodeficiency virus type 1 protease. , 1996, Journal of medicinal chemistry.
[20] R. Evans,et al. The steroid and thyroid hormone receptor superfamily. , 1988, Science.
[21] P. Goodford. A computational procedure for determining energetically favorable binding sites on biologically important macromolecules. , 1985, Journal of medicinal chemistry.
[22] H. Kubinyi. QSAR and 3D QSAR in drug design Part 1: methodology , 1997 .
[23] D S Goodsell,et al. Automated docking of flexible ligands: Applications of autodock , 1996, Journal of molecular recognition : JMR.
[24] Garland R. Marshall,et al. 3D-QSAR of angiotensin-converting enzyme and thermolysin inhibitors: A comparison of CoMFA models based on deduced and experimentally determined active site geometries , 1993 .
[25] Jack D. Dunitz,et al. Lone-pair directionality in hydrogen-bond potential functions for molecular mechanics calculations: the inhibition of human carbonic anhydrase II by sulfonamides , 1985 .
[26] Wolfgang Sippl,et al. Comparative Molecular Field Analysis of Aminopyridazine Acetylcholinesterase Inhibitors , 2000 .
[27] M. Pastor,et al. A strategy for the incorporation of water molecules present in a ligand binding site into a three-dimensional quantitative structure--activity relationship analysis. , 1997, Journal of medicinal chemistry.
[28] D. Lewis,et al. Molecular modelling of the human estrogen receptor and ligand interactions based on site-directed mutagenesis and amino acid sequence homology , 1995, The Journal of Steroid Biochemistry and Molecular Biology.
[29] K. Chae,et al. Three-dimensional quantitative structure-activity relationship study of nonsteroidal estrogen receptor ligands using the comparative molecular field analysis/cross-validated r2-guided region selection approach. , 1998, Journal of medicinal chemistry.
[30] T Lengauer,et al. CASP2 experiences with docking flexible ligands using FLEXX , 1997, Proteins.
[31] Tudor I. Oprea,et al. Three-dimensional quantitative structure-activity relationships of steroid aromatase inhibitors , 1996, J. Comput. Aided Mol. Des..
[32] T. Lybrand. Ligand-protein docking and rational drug design. , 1995, Current Opinion in Structural Biology.
[33] Hans-Joachim Böhm,et al. Prediction of binding constants of protein ligands: A fast method for the prioritization of hits obtained from de novo design or 3D database search programs , 1998, J. Comput. Aided Mol. Des..
[34] Jeremy R. H. Tame,et al. Scoring functions: A view from the bench , 1999, J. Comput. Aided Mol. Des..
[35] Hugo Kubinyi,et al. 3D QSAR in drug design : theory, methods and applications , 2000 .
[36] Toshio Fujita,et al. Classical and three-dimensional QSAR in agrochemistry : developed from a symposium sponsored by the Division of Agrochemicals at the 208th National Meeting of the American Chemical Society, Washington, DC, August 21-25, 1994 , 1995 .
[37] David A. Agard,et al. The Structural Basis of Estrogen Receptor/Coactivator Recognition and the Antagonism of This Interaction by Tamoxifen , 1998, Cell.
[38] F. Zeelen. Medicinal chemistry of steroids , 1990 .
[39] G. Cruciani,et al. Generating Optimal Linear PLS Estimations (GOLPE): An Advanced Chemometric Tool for Handling 3D‐QSAR Problems , 1993 .
[40] C. Wermuth,et al. 3-aminopyridazine derivatives with atypical antidepressant, serotonergic, and dopaminergic activities. , 1989, Journal of medicinal chemistry.
[41] G Klebe,et al. On the prediction of binding properties of drug molecules by comparative molecular field analysis. , 1993, Journal of medicinal chemistry.
[42] J. Mornon,et al. A model for the determination of the 3D-spatial distribution of the functions of the hormone-binding domain of receptors that bind 3-keto-4-ene steroids , 1992, The Journal of Steroid Biochemistry and Molecular Biology.
[43] Hans-Joachim Böhm,et al. The development of a simple empirical scoring function to estimate the binding constant for a protein-ligand complex of known three-dimensional structure , 1994, J. Comput. Aided Mol. Des..
[44] Zbigniew Dauter,et al. Molecular basis of agonism and antagonism in the oestrogen receptor , 1997, Nature.
[45] A. Maggi,et al. NEW ACETYLCHOLINESTERASE INHIBITORS , 1997 .
[46] Ki Hwan Kim,et al. Nonlinear dependence in comparative molecular field analysis , 1993, J. Comput. Aided Mol. Des..
[47] I. Kuntz. Structure-Based Strategies for Drug Design and Discovery , 1992, Science.
[48] Tudor I. Oprea,et al. Three-dimensional QSAR of human immunodeficiency virus (I) protease inhibitors. 1. A CoMFA study employing experimentally-determined alignment rules. , 1993, Journal of medicinal chemistry.
[49] A Tropsha,et al. Structure-based alignment and comparative molecular field analysis of acetylcholinesterase inhibitors. , 1996, Journal of medicinal chemistry.
[50] Han van de Waterbeemd,et al. Computer-Assisted Lead Finding and Optimization , 1997 .
[51] Larry R. McLean,et al. Evaluation of proposed modes of binding of (2S)-2-[4-[[(3S)-1-acetimidoyl-3-pyrrolidinyl]oxy]phenyl]-3-(7-amidino-2-naphthyl)propanoic acid hydrochloride and some analogs to Factor Xa using a comparative molecular field analysis , 1998, J. Comput. Aided Mol. Des..
[52] P. Mecocci,et al. Cognitive enhancement therapy for Alzheimer's disease. The way forward. , 1997, Drugs.